AbbVie: all 2,241 studies

Page 2 of 23. Open to participants first (134), then studies with results posted, then the rest; newest registration first within each.

• Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in BelgiumRecruitingNCT06581042
• Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult ParticipantsRecruitingNCT06575192Phase 3
• A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06568939Phase 2
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingNCT06548542Phase 2
• A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of LutikizumabRecruitingNCT06524635Phase 2
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06428019Phase 3
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) InfusionRecruitingNCT06158854Phase 1/2
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingNCT06100744Phase 3
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingNCT06084481Phase 1
• An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in JapanRecruitingNCT06023030
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05995353Phase 3
• Expanded Access to Telisotuzumab AdizutecanAvailableNCT05982873
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineRecruitingNCT05711394Phase 3
• Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineEnrolling by invitationNCT05707949Phase 3
• A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT05650632Phase 1
• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingNCT05609630Phase 3
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaRecruitingNCT05587049
• Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyEnrolling by invitationNCT05296447Phase 2
• Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDEnrolling by invitationNCT05210803Phase 2
• Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During PregnancyRecruitingNCT05158894
• Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)Enrolling by invitationNCT05127954Phase 3
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)RecruitingNCT05125302Phase 3
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingNCT05005403Phase 1
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Phase 3
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04895436Phase 2
• A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)Enrolling by invitationNCT04880876Phase 3
• Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved IndicationsRecruitingNCT04846959
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.RecruitingNCT04777357Phase 3
• Expanded Access to UpadacitinibAvailableNCT04159597
• Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyEnrolling by invitationNCT03999801Phase 2
• A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesRecruitingNCT03557619Phase 1
• Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingRecruitingNCT03342144
• Expanded Access to VenetoclaxAvailableNCT03123029
• A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial LinesCompletedNCT06218251Phase 4Results posted
• Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisCompletedNCT05969223Phase 4Results posted
• A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic DisorderTerminatedNCT05941442Phase 2Results posted
• A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult ParticipantsCompletedNCT05878067Phase 3Results posted
• Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineCompletedNCT05861427Phase 3Results posted
• Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative ColitisTerminatedNCT05785715Phase 2Results posted
• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's DiseaseCompletedNCT05771428Phase 2Results posted
• A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With LinaclotideCompletedNCT05760313Phase 2Results posted
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With MigraineCompletedNCT05748483Phase 3Results posted
• A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device in Adult Participants for the Appearance of CelluliteCompletedNCT05730335Phase 4Results posted
• A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device for the Appearance of Cellulite in Adult ParticipantsCompletedNCT05664581Phase 4Results posted
• A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional ConstipationCompletedNCT05652205Phase 3Results posted
• A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05601882Phase 3Results posted
• Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative ColitisCompletedNCT05570006Phase 2Results posted
• A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT05513703Phase 2Results posted
• A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05507580Phase 4Results posted
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaTerminatedNCT05443724Phase 2Results posted
• Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaTerminatedNCT05368558Phase 3Results posted
• JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck AppearanceCompletedNCT05316233Phase 3Results posted
• Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineCompletedNCT05264129Phase 4Results posted
• A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesCompletedNCT05248893Phase 3Results posted
• A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar LinesCompletedNCT05248880Phase 3Results posted
• A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesCompletedNCT05248867Phase 3Results posted
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227703Phase 2Results posted
• A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227690Phase 2Results posted
• Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineCompletedNCT05216263Phase 3Results posted
• A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead LinesCompletedNCT05152576Phase 2Results posted
• A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy ParticipantsCompletedNCT05138653Phase 1Results posted
• A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma ProminenceCompletedNCT05134649Phase 3Results posted
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedNCT05105841Phase 2Results posted
• A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar LinesCompletedNCT05100199Phase 2Results posted
• Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With CreonCompletedNCT05069597Phase 4Results posted
• A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's DiseaseTerminatedNCT05068284Phase 2Results posted
• A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe PsoriasisTerminatedNCT05044234Phase 2Results posted
• Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedNCT05041257Phase 2Results posted
• Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic MigraineTerminatedNCT05028569Phase 3Results posted
• A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar LinesCompletedNCT05013424Phase 2Results posted
• A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma ProminenceCompletedNCT04994535Phase 3Results posted
• A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice DailyCompletedNCT04983589Phase 3Results posted
• A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the RetinaCompletedNCT04976777Phase 3Results posted
• A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154TerminatedNCT04972968Phase 2Results posted
• A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related ApathyTerminatedNCT04958031Phase 2Results posted
• A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma ProminenceCompletedNCT04949399Phase 3Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental VitiligoCompletedNCT04927975Phase 2Results posted
• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus InfectionTerminatedNCT04913610Phase 2Results posted
• Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyCompletedNCT04908475Phase 4Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)CompletedNCT04903626Phase 3Results posted
• CoolSculpting® Elite for Non-Invasive Fat ReductionCompletedNCT04897867Phase 4Results posted
• JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese PopulationCompletedNCT04891419Phase 3Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)TerminatedNCT04888585Phase 2Results posted
• Effects on Cellulite AppearanceCompletedNCT04876118Not applicableResults posted
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisTerminatedNCT04853368Phase 2Results posted
• A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of AgeCompletedNCT04837482Phase 3Results posted
• Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineCompletedNCT04829747Phase 3Results posted
• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.CompletedNCT04740827Phase 3Results posted
• Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar InvolvementCompletedNCT04713592Phase 3Results posted
• An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresTerminatedNCT04686786Phase 2Results posted
• First-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsCompletedNCT04622774Phase 1/2Results posted
• Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial TreatmentCompletedNCT04609020Phase 4Results posted
• Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)CompletedNCT04542499Phase 3Results posted
• Functional Change With MMSCompletedNCT04506502Not applicableResults posted
• CoolSculpting SystemCompletedNCT04506307Not applicableResults posted
• Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult ParticipantsCompletedNCT04492020Phase 3Results posted
• Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT04477486Phase 2Results posted
• Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisCompletedNCT04472598Phase 3Results posted
• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateCompletedNCT04451772Phase 2Results posted

← AbbVie overview and focus areas